Rachel E. Sanborn

287 total papers · 8.9k total citations
153 papers, 3.6k citations indexed

About

Rachel E. Sanborn is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Rachel E. Sanborn has authored 153 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 124 papers in Oncology, 60 papers in Pulmonary and Respiratory Medicine and 35 papers in Immunology. Recurrent topics in Rachel E. Sanborn's work include Cancer Immunotherapy and Biomarkers (56 papers), Lung Cancer Treatments and Mutations (45 papers) and CAR-T cell therapy research (31 papers). Rachel E. Sanborn is often cited by papers focused on Cancer Immunotherapy and Biomarkers (56 papers), Lung Cancer Treatments and Mutations (45 papers) and CAR-T cell therapy research (31 papers). Rachel E. Sanborn collaborates with scholars based in United States, United Kingdom and France. Rachel E. Sanborn's co-authors include Ashok Gupta, Scott Antonia, Naiyer A. Rizvi, Ani Sarkis Balmanoukian, Joyson Karakunnel, Yu Gu, Keith E. Steele, Sarah B. Goldberg, Rajesh Narwal and Neil H. Segal and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Rachel E. Sanborn

146 papers receiving 3.6k citations

Hit Papers

normalize citations (0→100%) normalize lifespan (0→100%) sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

2016 660 citations Christophe Massard, Michael S. Gordon et al. Journal of Clinical Oncology profile →
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

2016 481 citations Scott Antonia, Sarah B. Goldberg et al. The Lancet Oncology profile →
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

2020 287 citations Makoto Nishio, Fabrice Barlési et al. Journal of Thoracic Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Rachel E. Sanborn	2.8k	1.3k	1.1k	740	511	153	3.6k
Mitsuhiro Takenoyama	2.2k 0.8×	1.9k 1.5×	1.1k 1.0×	963 1.3×	376 0.7×	222	3.9k
Takeshi Hanagiri	1.8k 0.6×	1.8k 1.4×	1.0k 0.9×	1.2k 1.6×	553 1.1×	209	3.9k
Alexander N. Shoushtari	3.3k 1.2×	825 0.6×	1.6k 1.4×	1.4k 1.9×	307 0.6×	166	4.7k
Leonard J. Appleman	1.5k 0.5×	1.2k 0.9×	758 0.7×	1.3k 1.8×	462 0.9×	177	3.3k
Dirk Jaeger	3.1k 1.1×	1.1k 0.9×	1.2k 1.0×	656 0.9×	1.0k 2.0×	90	4.2k
Jens Atzpodien	2.2k 0.8×	1.4k 1.1×	1.2k 1.1×	1.3k 1.8×	610 1.2×	141	3.9k
Erminia Massarelli	3.2k 1.2×	2.1k 1.6×	728 0.7×	1.2k 1.7×	505 1.0×	141	4.6k
Salvador Martín‐Algarra	2.2k 0.8×	926 0.7×	1.1k 1.0×	1.3k 1.8×	296 0.6×	142	3.9k
Carlos Gomez‐Roca	2.4k 0.9×	816 0.6×	784 0.7×	1.3k 1.7×	635 1.2×	148	4.0k
Jun Gong	2.1k 0.8×	832 0.6×	656 0.6×	907 1.2×	455 0.9×	163	3.3k

Countries citing papers authored by Rachel E. Sanborn

Since Specialization

Citations

This map shows the geographic impact of Rachel E. Sanborn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel E. Sanborn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel E. Sanborn more than expected).

Fields of papers citing papers by Rachel E. Sanborn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel E. Sanborn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel E. Sanborn. The network helps show where Rachel E. Sanborn may publish in the future.

Co-authorship network of co-authors of Rachel E. Sanborn

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel E. Sanborn. A scholar is included among the top collaborators of Rachel E. Sanborn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel E. Sanborn. Rachel E. Sanborn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Loading papers...

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact